不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel:ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Relapsed/Refractory Peripheral T-Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis With UNC13D and CD27 Germline Mutations.
Relapsed/Refractory Peripheral T-Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis With UNC13D and CD27 Germline Mutations.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
噬血细胞性淋巴组织细胞增多症(HLH)是一种严重的高炎症性疾病,可分为家族性和获得性。本研究报告一名26岁男性患者,患有复发/难治性外周T细胞淋巴瘤并发HLH。全外显子测序发现与HLH相关的胚系突变,包括CD27和UNC13D等关键基因,以及其他杂合胚系变异(NOTCH2、NOTCH3、IL2RA、TYK2、AGL、CFD和F13A1)。CD107a分析持续显示细胞毒性T淋巴细胞和自然杀伤(NK)细胞脱颗粒受损。家系调查发现患者父亲和母亲分别携带UNC13D和CD27突变,兄弟也携带相同的CD27杂合突变,但均未发病。尽管CD27错义变异(c.779C>T;p.Pro260Leu)此前未在数据库中记录,综合分析提示该变异无致病性,对T细胞和NK细胞功能影响很小。上述结果支持将造血干细胞移植(HSCT)作为成功的根治性治疗方案。截至报告时,患者在HSCT后15.2个月仍无淋巴瘤,HLH保持静止。
本研究强调,基因检测有助于识别重要突变并确认其病因,为尽早制定治疗方案及选择合适移植供者提供依据。
Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory disease characterized by familial and acquired forms.
Here, we present the case of a 26-year-old male patient with relapsed/refractory peripheral T-cell lymphoma and concurrent HLH. Whole-exon sequencing revealed germline mutations associated with HLH, including those in critical genes such as CD27 and UNC13D and other germline heterozygous variants ( NOTCH2, NOTCH3, IL2RA, TYK2, AGL, CFD , and F13A1 ).
CD107a analyses consistently demonstrated impaired degranulation of cytotoxic T-lymphocytes and natural killer (NK) cells. Examination of the patient's family pedigree revealed that his father and mother harbored UNC13D and CD27 mutations, respectively; his brother carried the same CD27 heterozygous mutation.
However, none of them manifested the disease. Despite the missense mutation of CD27 (c. 779C>T; p. Pro260Leu) lacking previous documentation in databases, comprehensive analysis suggested non-pathogenic mutations in the CD27 variant, indicating minimal impact on T- and NK-cell functions. These results ultimately supported the option of hematopoietic stem cell transplantation (HSCT) as a successful curative therapeutic approach. As of this report, the patient has remained free of lymphoma and quiescent HLH 15. 2 months post-HSCT.
This study underscores the efficacy of genetic tests in identifying significant mutations and confirming their etiologies, providing an early basis for treatment decisions and the selection of suitable transplant donors.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。